Literature DB >> 3531957

Argon laser photocoagulation treatment in central serous chorioretinopathy.

D M Robertson.   

Abstract

Central serous chorioretinopathy, a sporadic self-limited disease of young adults, is associated with loss of central vision, image distortion, and imparied dark adaptation. The diagnosis is verified with fluorescein angiography, which demonstrates and expanding point of fluorescein dye leakage under a serous detachment of the sensory retina. Treatment should ordinarily be delayed four or more months but may be considered if there is evidence of microarchitectural changes in the macular retina, if the best corrected visual acuity declines to 20/40 or less, or if there have been multiple recurrences. Argon laser photocoagulation should be directed to the leakage site, using spot sizes of 200 mu in diameter, exposure times of 0.2 seconds, and low-power intensities.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531957     DOI: 10.1016/s0161-6420(86)33652-2

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  17 in total

1.  Central serous chorioretinopathy after blunt trauma.

Authors:  Claudia Maria Prospero Ponce; Hasan M Mohidat; Charles A Garcia
Journal:  BMJ Case Rep       Date:  2012-05-26

2.  Selective retina therapy in patients with central serous chorioretinopathy.

Authors:  H Elsner; E Pörksen; C Klatt; A Bunse; D Theisen-Kunde; R Brinkmann; R Birngruber; H Laqua; J Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-12       Impact factor: 3.117

3.  Ophthaproblem. Central serous chorioretinopathy.

Authors:  S Sharma
Journal:  Can Fam Physician       Date:  1998-09       Impact factor: 3.275

4.  Surgical management of bilateral exudative retinal detachment associated with central serous chorioretinopathy.

Authors:  Ji Eun Kang; Hyun Jin Kim; Hee Don Boo; Ha Kyoung Kim; Jeong Hee Lee
Journal:  Korean J Ophthalmol       Date:  2006-06

5.  Angiographic characteristics of central serous chorioretinopathy in an Egyptian population.

Authors:  Maha M Shahin
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

6.  Photodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization-first report from the sultanate of oman.

Authors:  Upender Krishen Wali; Nadia Al-Kharousi; Harith Hamood
Journal:  Oman Med J       Date:  2008-10

7.  Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.

Authors:  Yoko Nomura; Ryo Obata; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2012-04-20       Impact factor: 2.447

8.  Indocyanine green enhanced subthreshold diode-laser micropulse photocoagulation treatment of chronic central serous chorioretinopathy.

Authors:  F Ricci; F Missiroli; F Regine; M Grossi; G Dorin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-17       Impact factor: 3.117

9.  The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.

Authors:  Stefan Hagen; Siamak Ansari-Shahrezaei; Eva Smretschnig; Carl Glittenberg; Ilse Krebs; Alexandra Graf; Susanne Binder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-29       Impact factor: 3.117

10.  Fundus autofluorescence in central serous chorioretinopathy: association with spectral-domain optical coherence tomography and fluorescein angiography.

Authors:  Peng Zhang; Hai-Yan Wang; Zi-Feng Zhang; Dong-Jie Sun; Jin-Ting Zhu; Juan Li; Yu-Sheng Wang
Journal:  Int J Ophthalmol       Date:  2015-10-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.